Skip to main content
Reimbursement strategy

Cost-effective market access strategy for medical technologies in Europe

A holistic approach to reimbursement strategies trusted by global market leaders and SMEs

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

NICE launched a refreshed support service for the life sciences industry

22 Nov 2023

On November 6, 2023, NICE announced the launch of its refreshed support service for pharmaceutical and health tech companies called “NICE Advice”. Service helps companies to prepare for a NICE evaluation or engagement with NHS payers and commissioners through three types of support: 

  • Advice - identifying gaps in evidence, providing actionable technical scientific advice on clinical and economic evidence plans, and quality-checking economic models;
  • Insight - facilitating access to valuable insight, ranging from a one-hour session with a NICE expert to a three-hour health system engagement meeting with a range of experts;
  • Education - a range of free webinars and paid seminars delivered online or in-person.  

These services are confidential and provided independently of NICE's guidance programs to ensure no conflicts of interest. 

See the full details here and here.

This news is just one of about 300 market access news collected by our team in the subscription service Market Access Monitor every week from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.